{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Octapinol, a substance with a low antibacterial activity that was studied to use in gingivitis and in stomatitis. Information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:nonapyrimine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nonapyrimine is an anticonvulsant, vasodilator.
Class (Stereo):
CHEMICAL (UNKNOWN)
Nonabine is a chromenol structurally related to the cannabinoids which has shown antiemetic efficacy in clinical trials. Nonabine also produced sedative clinical effects, but with an EEG profile which resembled that reportedly caused by cannabinoids. In contrast to cannabinoids, nonabine did not cause changes of mood or perception, suggesting that nonabine lacks the potential for social abuse at antiemetic doses. Nonabine was studied in the 1980s for the prevention of nausea and vomiting associated with cancer chemotherapy.
Status:
Investigational
Source:
INN:irsogladine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Irsogladine, a mucosal protective drug, was developed in Japan for the treatment of peptic ulcer disease and acute gastritis. Irsogladine increases intracellular cyclic adenosine 3',5'-monophosphate content via non-selective inhibition of phosphodiesterase isozymes and exhibits gastric cytoprotection partly mediated by endogenous nitric oxide. These effects may account for a variety of actions of irsogladine in the gastrointestinal tract, including facilitation of gap junctional intercellular communication, inhibition of the reduced gastric mucosal blood flow response, suppression of reactive oxygen generation and so on.
Status:
Investigational
Source:
INN:iprozilamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
IPROZILAMINE, a member of 4-piperazinopyrimidines, has powerful antiemetic activity. It also exhibits a relaxant effect on smooth muscle fiber.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ioxabrolic Acid is triiodobenzoic acid derivative and iodine-containing contrast media
Status:
Investigational
Source:
JAN:IPATASERTIB HYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ipatasertib, an investigational Akt inhibitor, is currently in clinical development based on its potential to specifically target Akt in tumors with activated Akt signaling. Preclinical data have shown that ipatasertib selectively decreased cell viability and increased apoptosis in tumor cell lines characterized by activated Akt. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer. The most commonly reported adverse events associated with Ipatasertib were Grade 1-2 diarrhea, nausea, fatigue, vomiting, decreased appetite and rash.
Class (Stereo):
CHEMICAL (RACEMIC)
Iomorinic Acid is triiodobenzamide derivative patented by Lentia G.m.b.H. as a radiographic contrast medium for liver imaging.
Status:
Investigational
Source:
INN:iodophthalein sodium [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Indorenate (TR3369, INDO) is a serotonin-like compound with high affinity for 5- HT1A receptors and a lower affinity for 5-HT1C and 5-HT1B receptors. Indorenate possesses antihypertensive and anxiolytic activity in animal behaviour tests. Similar to other serotonin receptor agonists, Indorenate also has anorectic activity; this effect was blocked by the administration of the 5-HT2A/2C receptor antagonists cinanserin, cyproheptadine, metergoline and methysergide. A unpublished clinical trial confirmed its antihypertensive activity in men.